NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient.

David A. Sallman, Jason Brayer, Elizabeth M. Sagatys, Caroline Lonez, Eytan Breman, Sophie Agaugué, Bikash Verma, David E. Gilham, Frédéric F. Lehmann, and Marco L. Davila

Disclosures: Some of the authors are employees of the sponsor of this trial and have equity in the company (CL, EB, SA, BV, DEG, FFL). MLD and DAS are compensated member of an advisory board for the company. There are no other disclosures.

Contributions: DAS, JB, EMS, CL, DEG, FL, BK, and MLD designed the trial. DAS and JB managed patients on the trial. EMS, CL, DAS, JB, EB, SA, DEG, FL, and MLD analyzed data from the trial. CL and EG and SA prepared experiments. All authors wrote and edited the manuscript.